Semaglutide 7.2 mg is a higher-dose, once-weekly GLP-1 receptor agonist developed by Novo Nordisk for chronic weight management in adults with obesity. It contains the same active ingredient as the established 2.4 mg treatment, with a higher maintenance dose that may provide additional weight loss for selected patients following gradual dose escalation.
In the 72-week STEP UP trial, adults with obesity without diabetes achieved an average weight reduction of 18.7% with semaglutide 7.2 mg, compared with 15.6% with 2.4 mg, regardless of treatment adherence. Both groups also received lifestyle intervention. This represents approximately 3.1 percentage points of additional average weight loss, although individual results vary and the higher dose carries a greater likelihood of certain side effects. A separate trial, STEP UP T2D, evaluated treatment in adults with obesity and type 2 diabetes.
Semaglutide 7.2 mg is not a starting dose. Treatment requires a prescription and an individual medical assessment, considering previous treatment response, tolerability and overall health. In this guide, Dr Edwin Lim explains the clinical evidence, dosing, side effects and suitability of semaglutide 7.2 mg for doctor-supervised weight management in Singapore.
A higher dose is not automatically the right dose for every patient. When considering semaglutide 7.2 mg, my priority is whether the additional weight loss could meaningfully improve a patient’s health while maintaining acceptable tolerability.
The STEP UP results help inform this discussion, but trial averages cannot determine the best dose for an individual. Treatment decisions should account for the response to 2.4 mg, remaining obesity-related health concerns, side effects and the sustainability of the treatment plan.
An increase to semaglutide 7.2 mg may be considered for patients who:
Patients who are achieving meaningful health improvements and satisfactory weight loss on 2.4 mg may have little reason to increase their dose. Persistent nausea, vomiting or difficulty maintaining adequate nutrition and hydration also warrant reassessment before considering escalation.
A weight-loss plateau alone does not mean treatment has failed or that a higher dose is necessary. The decision should consider the overall progress already achieved, including improvements in health, physical function and quality of life.
My approach is to individualise treatment, with continued attention to nutrition, muscle health and tolerability as weight changes.
Semaglutide 7.2 mg may be considered for selected adults with obesity who need additional weight reduction and tolerate semaglutide 2.4 mg. Suitability depends on medical history, treatment response and the potential benefits and risks of increasing the dose.
At Edwin Lim Medical Aesthetic Clinic, assessment includes a review of weight history, obesity-related conditions, current medications and previous treatment tolerability.
Doctors may consider the higher dose for patients who:
Meeting a BMI threshold does not automatically make someone suitable for 7.2 mg. Previous use of another GLP-1 medication also does not justify switching directly to this dose.
Learn more about semaglutide 2.4 mg in our weight-management guide:
https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
Semaglutide should not be used during pregnancy or breastfeeding, or by patients with a known serious allergy to semaglutide or its ingredients. It should be stopped at least two months before a planned pregnancy.
Additional assessment is necessary for patients with:
The prescribing information for the specific product used should guide the final assessment.
Type 2 diabetes does not automatically exclude a patient. The STEP UP T2D trial specifically studied semaglutide 7.2 mg in adults with obesity and type 2 diabetes. Suitability requires consideration of both weight-management needs and diabetes care.
Patients taking insulin or sulfonylureas may need medication adjustments to reduce the risk of low blood glucose. Semaglutide must not replace prescribed insulin.
Semaglutide 7.2 mg supports weight loss primarily by reducing appetite and calorie intake. It belongs to a group of medications called GLP-1 receptor agonists, which mimic the action of glucagon-like peptide-1, a naturally occurring hormone involved in appetite and blood glucose regulation.
By activating GLP-1 receptors in the brain, semaglutide helps regulate hunger, fullness and food cravings. Patients may feel satisfied with smaller portions and find it easier to reduce their food intake. These effects support weight management alongside appropriate nutrition, physical activity and behavioural changes.
Semaglutide can also slow gastric emptying, meaning food leaves the stomach more slowly. However, its weight-loss effects are primarily attributed to appetite regulation and reduced calorie intake.
When blood glucose is elevated, semaglutide stimulates insulin release and reduces glucagon secretion, helping to lower blood glucose. This is particularly relevant for patients who also have type 2 diabetes.
Learn more about GLP-1 weight-loss injections in Singapore:
https://edwinlimclinic.sg/weekly-glp-1-weight-loss-injections-singapore-ozempic-wegovy-mounjaro/
Both doses contain the same active ingredient and act through the same GLP-1 pathway. The 7.2 mg dose increases exposure to semaglutide, which may provide additional weight reduction for selected patients.
However, three times the dose does not mean three times the weight loss. The additional benefit varies between individuals and must be considered alongside side effects and the response already achieved with 2.4 mg. Progression to 7.2 mg requires gradual, doctor-supervised dose escalation and an assessment of tolerability.
STEP UP was an international Phase 3b clinical trial investigating whether semaglutide 7.2 mg could provide additional weight loss beyond the established 2.4 mg dose, while assessing safety and tolerability.
| Trial feature | Details |
| Study design | Randomised, double-blind trial with active-treatment and placebo comparison groups |
| Participants | 1,407 adults aged 18 or older with a BMI of at least 30 kg/m², without diabetes |
| Treatment groups | Once-weekly semaglutide 7.2 mg, semaglutide 2.4 mg or placebo |
| Duration | 72 weeks |
| Lifestyle intervention | Reduced-calorie diet and increased physical activity in all groups |
| Primary outcomes | Percentage change in body weight and the proportion achieving at least 5% weight loss |
Researchers also assessed larger weight-loss thresholds, changes in waist circumference, side effects and treatment discontinuation. Participants assigned to semaglutide began at a low dose and underwent gradual escalation.
The direct comparison with 2.4 mg allowed researchers to measure the additional benefit of the higher dose. Patients with diabetes were studied separately in STEP UP T2D.
In STEP UP, semaglutide 7.2 mg produced greater average weight loss at 72 weeks than semaglutide 2.4 mg or placebo. Two analyses were reported, reflecting different assumptions about treatment continuation and the use of other weight-management treatments.
| Analysis | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
| Regardless of treatment discontinuation or additional weight-management treatment | 18.7% | 15.6% | 3.9% |
| Assuming continued assigned treatment without additional weight-management treatment | 20.7% | 17.5% | 2.4% |
These percentages represent average reductions from starting body weight.
The treatment-policy analysis estimates the effect of assignment to treatment, including what happened when participants stopped treatment or received other weight-management interventions.
The trial-product analysis estimates the effect assuming participants continued their assigned treatment without adding other weight-loss medication or undergoing bariatric surgery.
Both analyses describe outcomes within a controlled clinical trial; individual results in everyday practice may differ.
The difference between the two doses was approximately 3.1–3.2 percentage points of starting body weight, depending on the analysis.
This is a comparison between groups treated from the beginning of the trial. It does not mean that someone already taking 2.4 mg should expect to lose another 3.1–3.2% after increasing to 7.2 mg. STEP UP was not specifically designed to test dose escalation in patients who had plateaued after long-term treatment with 2.4 mg.
Learn more about semaglutide 2.4 mg:
https://edwinlimclinic.sg/wegovy-weight-loss-singapore-guide/
The trial also examined the proportion of participants reaching different weight-loss thresholds.
| Weight reduction achieved at 72 weeks | Semaglutide 7.2 mg | Semaglutide 2.4 mg | Placebo |
| At least 5% | 90.7% | 89.9% | 36.8% |
| At least 10% | 82.4% | 75.1% | 20.5% |
| At least 15% | 66.5% | 54.5% | 7.6% |
| At least 20% | 47.7% | 33.3% | 2.9% |
| At least 25% | 31.2% | 15.3% | 0% |
These are observed proportions based on available in-trial measurements, regardless of treatment discontinuation or changes. They differ from model-based estimates that account for missing measurements.
Almost half of participants with available measurements in the 7.2 mg group achieved at least 20% weight loss, and approximately one in three achieved at least 25%. However, individual responses varied considerably.
Trial averages and responder rates help explain the range of possible outcomes, but they cannot predict an individual patient’s weight loss. Treatment response depends on factors including tolerability, adherence, nutrition, physical activity and existing medical conditions.
For clinical decision-making, the potential additional weight reduction should be considered alongside side effects, nutritional status and improvements in obesity-related health concerns.
Weight loss during semaglutide treatment can include reductions in both body fat and lean tissue, including muscle. Supporting muscle health through appropriate nutrition and resistance exercise is therefore an important part of treatment.
A STEP UP substudy used MRI scans to assess body composition in 55 participants. It found that semaglutide treatment was associated with a greater reduction in fat than lean tissue over 72 weeks. However, this small substudy does not establish that muscle is fully preserved or predict the proportion of fat and muscle an individual patient will lose.
Supporting muscle health should form part of a medical weight-management plan. Measures include:
Patients who develop persistent weakness, difficulty eating enough or a noticeable decline in physical function should discuss these changes with their doctor. Treatment reviews should consider nutritional intake and muscle health alongside weight reduction.
Semaglutide 7.2 mg can cause gastrointestinal symptoms and changes in skin sensation. Some side effects occur more frequently than with 2.4 mg, making tolerability an important consideration when increasing the dose.
Commonly reported side effects of semaglutide include:
Gastrointestinal symptoms often occur during dose escalation and may improve over time. However, persistent symptoms, difficulty eating or drinking, or disruption to daily activities warrant a treatment review.
The published STEP UP trial reported the following adverse-event rates:
| Adverse event | Semaglutide 7.2 mg | Semaglutide 2.4 mg |
| Gastrointestinal adverse events | 70.8% | 61.2% |
| Altered skin sensations, reported as dysaesthesia | 22.9% | 6.0% |
Dysaesthesia can involve unusual sensitivity, tingling, burning or discomfort when the skin is touched. Patients experiencing new or persistent skin sensations should inform their doctor, as other possible causes may also require assessment.
The reported events varied in severity, and individual tolerability differed.
Potentially serious risks include pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney injury and allergic reactions.
Seek urgent medical assessment for:
Stop treatment and seek emergency help for breathing difficulty or swelling of the face, lips, tongue or throat. Severe, persistent abdominal pain also requires withholding further doses until assessed for possible pancreatitis.
Low blood glucose is another concern, particularly in patients taking insulin or sulfonylureas. These medications may require adjustment during treatment.
For mild gastrointestinal symptoms, practical measures include:
If symptoms persist, a doctor may delay escalation, reduce the dose or temporarily pause treatment. Patients should not increase their dose while experiencing significant side effects.
Semaglutide injections can be administered with or without food.
Semaglutide 7.2 mg is a maintenance dose for selected patients, rather than a starting dose. Treatment begins with a medical assessment and a dosing plan based on previous medication use, treatment response and tolerability.
At Edwin Lim Medical Aesthetic Clinic, your consultation includes a review of:
Blood tests may be recommended where clinically indicated. The assessment determines whether semaglutide is appropriate and whether a higher maintenance dose is justified.
For patients starting semaglutide, the usual escalation schedule is:
| Treatment period | Once-weekly dose |
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1.0 mg |
| Weeks 13–16 | 1.7 mg |
| Weeks 17–20 | 2.4 mg |
| Week 21 onwards | Continue 2.4 mg, or consider 7.2 mg if clinically indicated and tolerated |
An increase to 7.2 mg may be considered after at least four weeks on 2.4 mg. Progression is not automatic: patients experiencing significant side effects may need a longer period at their current dose or a treatment adjustment.
Patients already receiving semaglutide require a review of their current dose and any treatment interruptions to determine the appropriate next step. Switching from another GLP-1 medication requires an individual dosing plan.
Your doctor or clinic team will also explain the injection technique, storage requirements and instructions for the prescribed pen.
Follow-up appointments assess weight changes, side effects, nutritional intake and progress towards health goals. Monitoring may also include blood glucose, blood pressure, muscle function or blood tests, depending on individual needs.
The maintenance dose and duration of treatment are reviewed according to clinical benefit and tolerability, with continued support for nutrition and physical activity.
Arrange a medical weight-management consultation:
https://edwinlimclinic.sg/contact/
A consultation can help determine whether your current weight-management treatment remains appropriate or whether a higher maintenance dose should be considered. Dr Edwin Lim will review your treatment response, medical history and health goals before discussing suitable options.
Learn more about our personalised medical weight-management programme:
https://edwinlimclinic.sg/personalised-medical-weight-loss-program-in-singapore/
To arrange a consultation:
Contact details and appointment enquiries:
https://edwinlimclinic.sg/contact/
Dr Edwin Lim
MBBS (Singapore), MRCS (Edinburgh), PgDip Practical Dermatology (Cardiff), MSc Practical Dermatology (Cardiff), Diploma in Aesthetic Medicine, (AAAM), Accredited by the Aesthetic Dermatology Educational Group (ADEG)
